AM Best highlights GLP-1 insurance cost pressures in podcast discussion
Rising use of GLP-1 therapies is sharpening a key cost and benefits debate for health insurers as drug spending climbs across the sector. The issue carries long-term implications for pharmacy trends, employer and health plan benefit design, and broader health care economics.
Highlights
- AM Best Director Joseph Zazzera states GLP-1 therapies are driving increased pharmacy spending for health insurers, raising near-term cost pressures.
- Insurer utilization of GLP-1 therapies has accelerated significantly, causing immediate and measurable pharmacy expense impacts with longer-term benefits uncertain.
- GLP-1 adoption continues to influence benefit design decisions in the insurance industry, making it a critical focus for managing pharmacy trend risks.
Podcast discussion focuses on insurer cost trade-offs
As reported by AM Best, Director Joseph Zazzera appears on an episode of the “Pulse of Prevention” podcast to discuss GLP-1 therapies and their implications for insurance companies.In the episode, Zazzera says GLP-1 therapies have become a driver of pharmacy spending as health insurers continue to balance higher near-term drug costs against the potential for lower overall medical costs in the future. He says utilization of the therapies has significantly accelerated, creating a strategic challenge because pharmacy expenses are immediate and measurable while many expected benefits may not be realized for years.
Sector implications for health insurers
AM Best says GLP-1 therapies remain one of the insurance industry's most closely watched developments because they are influencing pharmacy trends and decisions on employer and health plan benefit design.Zazzera has been with AM Best for more than two decades and oversees a team of analysts covering multiline, domestic and international insurers, with a focus on health- and benefits-related segments. His comments on the podcast underscore how insurers are weighing current cost pressure against possible longer-term health and economic gains.
Our earlier coverage of the FDA approval of Eli Lilly’s once-weekly basal insulin Onswik explained how the new option could reduce injection frequency for adults with type 2 diabetes and intensify competition in the long-acting insulin market. We also outlined the planned U.S. launch timeline, trial results supporting the decision, and key usage limits such as avoiding use in type 1 diabetes due to hypoglycemia risk.